Hemodynamic Profiles in Symptomatic Patients with Severe Aortic Stenosis Referred for Aortic Valve Replacement: Experience at a Tertiary Care Center in the Middle East

2020 ◽  
Vol 4 (sup1) ◽  
pp. 92-93
Author(s):  
Mohammed Khalil ◽  
Firas Al Badarin ◽  
Shahrukh Hashmani ◽  
Fahad Shamsi ◽  
Khwaja Yousuf Hasan ◽  
...  
Open Heart ◽  
2019 ◽  
Vol 6 (2) ◽  
pp. e001019 ◽  
Author(s):  
Tanja K. Rudolph ◽  
David Messika-Zeitoun ◽  
Norbert Frey ◽  
Matthias Lutz ◽  
Laura Krapf ◽  
...  

BackgroundSevere aortic stenosis (AS) is one of the most common and most serious valve diseases. Without timely intervention with surgical aortic valve replacement or transcatheter aortic valve replacement, patients have an estimated survival of 2–3 years. Guidelines for the treatment of AS have been developed, but studies suggest that as many as 42% of patients with AS are not treated according to these recommendations.The aims of this registry are to delineate the caseload of patients with AS, outline the management of these patients and determine appropriateness of treatments in participating centres with and without onsite access to surgery and percutaneous treatments.Methods/designThe IMPULSE enhanced registry is an international, multicentre, prospective, observational cohort registry conducted at four central full access centres (tertiary care hospitals) and at least two satellite centres per hub (primary/secondary care hospitals). An estimated 800 patients will be enrolled in the registry and patient follow-up will last for 12 months.DiscussionIn addition to the primary aims determining the caseload management and outcome of patients with AS in primary, secondary and tertiary care settings, the registry will also determine a time course for the transition from asymptomatic to symptomatic status and the diagnostic steps, treatment decisions and the identification of decision-makers in tertiary versus primary/secondary care hospitals. The last patient will be enrolled in the registry in 2018 and results of the registry are anticipated in 2019.Registration numberNCT03112629.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Charbel Abi Khalil ◽  
Barbara Ignatiuk ◽  
Guliz Erdem ◽  
Hiam Chemaitelly ◽  
Fabio Barilli ◽  
...  

AbstractTranscatheter aortic valve replacement (TAVR) has shown to reduce mortality compared to surgical aortic valve replacement (sAVR). However, it is unknown which procedure is associated with better post-procedural valvular function. We conducted a meta-analysis of randomized clinical trials that compared TAVR to sAVR for at least 2 years. The primary outcome was post-procedural patient-prosthesis-mismatch (PPM). Secondary outcomes were post-procedural and 2-year: effective orifice area (EOA), paravalvular gradient (PVG) and moderate/severe paravalvular leak (PVL). We identified 6 trials with a total of 7022 participants with severe aortic stenosis. TAVR was associated with 37% (95% CI [0.51–0.78) mean RR reduction of post-procedural PPM, a decrease that was not affected by the surgical risk at inclusion, neither by the transcatheter heart valve system. Postprocedural changes in gradient and EOA were also in favor of TAVR as there was a pooled mean difference decrease of 0.56 (95% CI [0.73–0.38]) in gradient and an increase of 0.47 (95% CI [0.38–0.56]) in EOA. Additionally, self-expandable valves were associated with a higher decrease in gradient than balloon ones (beta = 0.38; 95% CI [0.12–0.64]). However, TAVR was associated with a higher risk of moderate/severe PVL (pooled RR: 9.54, 95% CI [5.53–16.46]). All results were sustainable at 2 years.


2002 ◽  
Vol 89 (4) ◽  
pp. 408-413 ◽  
Author(s):  
Harald P Kühl ◽  
Andreas Franke ◽  
David Puschmann ◽  
Friedrich A Schöndube ◽  
Rainer Hoffmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document